“A combination of the drugs raltegravir and lamivudine produced acceptable drug levels in both women and men, in rectal and vaginal tissues, suggesting that the two drugs could provide an effective alternative to tenofovir-based pre-exposure prophylaxis (PrEP), the 25th Annual Conference of the British HIV Association (BHIVA) heard in Bournemouth yesterday.”
For more, click here.